Semaglutide may help liver

Semaglutide may help the liver directly, not just through weight loss, according to new human trial analyses and a mouse study published in April. (utoronto.ca) Semaglutide is a GLP-1 drug, a class used for type 2 diabetes and obesity under brands including Ozempic and Wegovy. In a Cell Metabolism paper published in April 2026, researchers at Sinai Health and the University of Toronto reported that the drug acted on liver sinusoidal endothelial cells, a subset of cells lining tiny liver blood vessels, in mice with metabolic dysfunction-associated steatohepatitis. (cell.com) Metabolic dysfunction-associated steatohepatitis, or MASH, is an advanced form of fatty liver disease in which fat buildup is followed by inflammation and scarring that can progress to cirrhosis and liver failure. Sinai Health said the condition could affect nearly 2 billion people worldwide by 2050. (sinaihealth.ca) The mouse study helps explain a pattern doctors had already seen in people taking semaglutide. Daniel Drucker of Sinai Health said clinical trials had shown that patients who lost very little weight could still see reductions in liver inflammation, scarring and enzyme levels. (utoronto.ca) One of those human datasets came from the phase 3 ESSENCE trial in adults with biopsy-defined MASH and stage 2 or 3 fibrosis. In part 1, 800 patients were randomized to semaglutide 2.4 milligrams weekly or placebo, and at week 72 semaglutide was linked to steatohepatitis resolution without worsening fibrosis in 62.9% of patients versus 34.3% on placebo, while fibrosis improved without worsening steatohepatitis in 36.8% versus 22.4%. (pmc.ncbi.nlm.nih.gov) That same ESSENCE secondary analysis found liver benefits across weight-loss bands, including modest loss of 2% to 5% of body weight. In that subgroup, steatohepatitis resolution rates were 57.1% with semaglutide and 43.1% with placebo, while fibrosis improvement rates were 29.3% and 22.5%. (pmc.ncbi.nlm.nih.gov) A separate Nature Medicine analysis published on April 2, 2026 looked at people in the SELECT cardiovascular outcomes trial who were at high risk for liver fibrosis. Over 104 weeks, semaglutide was associated with a 28% greater decrease than placebo in fatty liver index, a noninvasive score that estimates liver fat. (nature.com) The new mechanistic study does not prove that every liver benefit in humans comes from the same pathway seen in mice. It does, however, give researchers a concrete target in the liver itself after years of debate over whether liver cells carried enough GLP-1 receptor activity for semaglutide to act there directly. (cell.com) That leaves two tracks running at once: semaglutide still lowers weight and improves blood sugar, and some liver effects may also come from local anti-inflammatory and anti-scarring signaling inside the organ. The next step is to test how much of that mouse mechanism shows up in patients with MASH and other forms of fatty liver disease. (cell.com)